ClinicalTrials.gg
CompletedNCT00280917Updated Sep 18, 2023Results posted

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

A Phase 2 interventional study of CF101 in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Completed at 35 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Arthritis, Rheumatoid with a site in Israel — 3 open to participants now, 5 under way, 2 of them phase 3. Arthritis, Rheumatoid · Israel.

Enrollment
47th of 74
254 · median 496
Started
2006
with 1 other
Phase 2
14 of 83
none open now
Registered
9th of 83
by date
Lead sponsor
4 of 83
Can-Fite BioPharma

Among the 83 studies in Arthritis, Rheumatoid with a site in Israel, this one is the 47th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 2, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 83 studies in Arthritis, Rheumatoid with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Arthritis, Rheumatoid with a site in Israel, or all of them as a file.
02

Study summary

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

Read the detailed description

This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose-finding study in which patients with active RA despite receiving methotrexate for at least 6 months (at unchanged doses for >=2 months) will be randomized to the addition of either CF101 0.1 mg, CF101 1 mg, CF101 4 mg, or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, duration of morning stiffness, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, 12, and 14.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • RA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ages 18-75 years
  • Meet the criteria of the American Rheumatism Association for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324, Appendix 1)
  • Not bed- or wheelchair-bound
  • Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND at least one of the following: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the for the central reference laboratory; OR (e) morning stiffness for >=45 minutes
  • Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline
  • Methotrexate route of administration has been unchanged for >=2 months prior to baseline
  • Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose
  • If taking hydroxychloroquine, administration duration has been >=3 months and dose has been stable for >=2 months prior to baseline
  • If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation
  • If taking an oral , dose is \<=10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the , and will remain stable through the washout and entire treatment and follow-up period
  • Absence of findings, such as interstitial pneumonitis or active pulmonary infection, on chest X-ray taken within 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Receipt of any of the following for at least a 1 month prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra
  • Receipt of etanercept for at least a 6 week period prior to dosing
  • Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing
  • Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing
  • Receipt of cyclophosphamide for at least a 6 month period prior to dosing
  • Receipt of rituximab at any previous time
  • Receipt of CF101 in a previous trial
  • Use of oral >10 mg of prednisone, or equivalent, per day
  • Change in NSAID dose level for 1 month prior to dosing
  • Change in oral corticosteroid dose level during the 1 month prior to, or during, the washout period
  • Change in hydroxychloroquine dose level during the 2 months prior to, or during, the washout period
  • Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the washout period
  • Presence or history of uncontrolled asthma
  • Presence or history of uncontrolled arterial hypertension or symptomatic hypotension
  • Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of heart disease; other clinically significant findings on screening (ECG)
  • level \<9.0 gm/L
  • count \<125,000/mm3
  • White blood cell count \<3000/mm3
  • Serum creatinine level outside the laboratory's normal limits
  • Liver aminotransferase levels greater than 1.2 times the laboratory's
  • Known or suspected immunodeficiency or positivity
  • Pregnancy, lactation, or inadequate as judged by the Investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
254 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. ACR Efficacy Criteria

    ACR 20 response (20% improvnent in RA based on swollen and tender joint counts, physician and patient global assessments of disease activity, a patient pain score) at endpoint (Week 12), with all-cause dropouts considered as nonresponders (nonresponder imputation) in the Intent-To-Treat (ITT) population

    Time frame: 12 weeks

Secondary outcomes

  1. ACR Criteria Components

    ACR 20 response at all visits in the evaluable population and ACR 50 and ACR 70 responses at all visits in the ITT and evaluable populations using both nonresponder imputation and Last Observation Carried Forward (LOCF) analyses; change and percent change from baseline at each visit in the ITT and evaluable populations, analyzed using LOCF, in ACR response components \[tender joint count, swollen joint count, patient assessment of pain by VAS, patient global assessment of disease activity by VAS, physician global assessment of disease activity by VAS, HAQ DI, CRP (by central laboratory, using an standard-sensitivity assay capable of detecting changes below the upper limit of normal) and ESR\], Disease Activity Score (DAS28), and duration of morning stiffness.

    Time frame: 12 weeks

  2. Safety

    Vital signs and weight, physical examinations, adverse event (AE) reporting, clinical laboratory testing, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing and 12-lead resting ECGs

    Time frame: 12 weeks

07

Results

Posted Mar 17, 2015

Participant flow

Participant flow — Overall Study
MilestoneCF101 0.1mgCF101 1mgCF101 4mgPlacebo
Started65636363
Completed63575761
Not completed2662
Withdrew: Adverse event1141
Withdrew: Change therapy1200
Withdrew: Withdrawal by subject0201
Withdrew: Noncompliance0120

Outcome measures

PrimaryACR Efficacy Criteria

ACR 20 response (20% improvnent in RA based on swollen and tender joint counts, physician and patient global assessments of disease activity, a patient pain score) at endpoint (Week 12), with all-cause dropouts considered as nonresponders (nonresponder imputation) in the Intent-To-Treat (ITT) population

Time frame:
12 weeks
Reported as:
Number · participants
ACR Efficacy Criteria
participantsCF101 0.1 mgCF101 1 mgCF101 4 mgPlacebo
ACR Efficacy Criteria63575761
SecondaryACR Criteria Components

ACR 20 response at all visits in the evaluable population and ACR 50 and ACR 70 responses at all visits in the ITT and evaluable populations using both nonresponder imputation and Last Observation Carried Forward (LOCF) analyses; change and percent change from baseline at each visit in the ITT and evaluable populations, analyzed using LOCF, in ACR response components \[tender joint count, swollen joint count, patient assessment of pain by VAS, patient global assessment of disease activity by VAS, physician global assessment of disease activity by VAS, HAQ DI, CRP (by central laboratory, using an standard-sensitivity assay capable of detecting changes below the upper limit of normal) and ESR\], Disease Activity Score (DAS28), and duration of morning stiffness.

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondarySafety

Vital signs and weight, physical examinations, adverse event (AE) reporting, clinical laboratory testing, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing and 12-lead resting ECGs

Time frame:
12 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 0.1mg—2/63 (3.2%)0/63 (0%)
CF101 1mg—2/57 (3.5%)0/57 (0%)
CF101 4mg—2/57 (3.5%)0/57 (0%)
Placebo—0/61 (0%)0/61 (0%)
Most frequent serious events
Most frequent serious events
EventCF101 0.1mgCF101 1mgCF101 4mgPlacebo
PNEUMONIA VIRALISInfections and infestations0/631/570/570/61
hepatitis acuteInfections and infestations0/630/571/570/61
COPD EXACERBATIONRespiratory, thoracic and mediastinal disorders0/631/570/570/61
Supposition of Chronic BronchitisInfections and infestations0/630/571/570/61
Visual DisturbanceEye disorders1/630/570/570/61
Non small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/630/570/570/61

Baseline characteristics

Age, Continuous
Age, Continuous(years)CF101 0.1mgCF101 1mgCF101 4mgPlaceboTotal
Mean54.7 ± 12.0254.3 ± 9.9854.4 ± 10.0753 ± 10.8654.1 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)CF101 0.1mgCF101 1mgCF101 4mgPlaceboTotal
Female49465252199
Male1617111155
08

Study locations

35 sites
  • Can-Fite Investigational Site
    Peoria, Arizona 85381, United States
  • Can-Fite Investigational Site
    Albany, New York 12206, United States
  • Can-Fite Invesitigational Site
    Cleveland, Ohio 44195, United States
  • Can-Fite Investigational Site
    Perrysburg, Ohio 43551, United States
  • Can-Fite Investigational Site
    Sugar Land, Texas 77479, United States
  • Can-Fite Investigational Site
    Plovdiv, 4002, Bulgaria
  • Can-Fite Investigational Site
    Sofia, 1233, Bulgaria
  • Can-Fite Investigational Site
    Sofia, 1612, Bulgaria
  • Can-Fite Investigational Site
    Stara Zagora, 6000, Bulgaria
  • Can-Fite Investigational Sites
    Afula, Israel
  • Can-Fite Investigational Site
    Ashkelon, 78278, Israel
  • Can-Fite Investigational Site
    Beer Yaakov, 70300, Israel
  • Can-Fite Investigational Site
    Haifa, 31096, Israel
  • Can-Fite Investigational Site
    Haifa, 77479, Israel
  • Can-Fite Investigational Site
    Jerusalem, 91031, Israel
  • Can-Fite Investigational Site
    Jerusalem, 91120, Israel
  • Can-Fite Investigational Site
    Jerusalem, Israel
  • Can-Fite Investigational Site
    Kfar-Saba, 44281, Israel
  • Can-Fite Investigational Site
    Tel Hashomer, 52621, Israel
  • Can-Fite Investigational Site
    Białystok, 15-297, Poland
  • Can-Fite Investigational Site
    Lublin, 20-022, Poland
  • Can-Fite Investigational Site
    Sopot, 81-759, Poland
  • Can-Fite Investigational Site
    Szczecin, 71-252, Poland
  • Can-Fite Investigational Site
    Brasov, 500356, Romania
  • Can-Fite Investigational Site
    Bucharest, 020125, Romania
  • Can-Fite Investigational Site
    Bucharest, 020983, Romania
  • Can-Fite Investigational Site
    Cluj Napoca, 400006, Romania
  • Can-Fite Investigational Site
    Iasi, 700661, Romania
  • Can-Fite Investigational Site
    Belgrade, 11000, Serbia
  • Can-Fite Investigational Site
    Niska Banja, 18205, Serbia
  • Can-Fite Investigational Site
    Zemun, 11080, Serbia
  • Can-Fite Investigational Site
    Kiev,, 01023, Ukraine
  • Can-Fite Investigational Site
    Kiev,, 01103, Ukraine
  • Can-Fite Investigational Site
    Kiev, 03680, Ukraine
  • Can-Fite Investigational Site
    Kiev, 04053, Ukraine
09

References and documents

Publications

  • Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol. 1998 Sep;125(2):379-87. doi: 10.1038/sj.bjp.0702040. PubMed 9786512 ↗
  • Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005 Mar;32(3):469-76. PubMed 15742438 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 7 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2006
First posted
Jan 24, 2006
Start
Jun 2006
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Results first posted
Mar 17, 2015
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00280917
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Jan 24, 2006
Start date
Jun 2006
Primary completion
Apr 2007
Completion
Apr 2007
Results posted
Mar 17, 2015
Last update
Sep 18, 2023

Study contacts

Michael H Silverman, MD
study director · BioStrategics Consulting Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion